Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Clin Rheumatol

Search In Journal Title:

Abbravation: Clinical Rheumatology

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

ISSN

1434-9949

Search In ISSN:
Search In Title Of Papers:

The impact of current healthrelated quality of li

Authors: Barbara Sokołowska Wojciech Szczeklik Olga Piłat Michał Wodkowski Justyna Pieczątka Jolanta Gąsior Katarzyna Szczeklik Anna Włudarczyk Karolina Pacułt Jacek Musiał
Publish Date: 2013/01/18
Volume: 32, Issue: 6, Pages: 779-785
PDF Link

Abstract

Eosinophilic granulomatosis with polyangiitis EGPA is a rare autoimmune small and medium vessel vasculitis EGPA is accompanied by asthma and involves mainly the blood vessels of the lungs gastrointestinal system and peripheral nerves however the skin kidneys and heart may be also affected To investigate if patients with EGPA experience reduced healthrelated quality of life HRQOL and the effect of this parameter on their own perception of future health outlook Twentysix EGPA patients are in disease remission and completed a customdesigned questionnaire and the Medical Outcomes Study Short Form 36 SF36 Using the RAND method eight HRQOL dimensions were calculated general health physical functioning emotional role limitations physical role limitations social functioning mental health bodily pain and vitality Using normbased scores the HRQOL of patients was compared with that of the general population EGPA patients had decreased HRQOL across all eight dimensions of the SF36 Patients with higher mental component score felt more positive about their future health while patients with low physical component score were likely not to feel negatively about their future health Also 36  of older patients 50 years had a positive outlook compared to 47  of younger patients 50 years and patients with a longer disease course were much less likely to have a positive outlook 30  positive than those with a shorter course 50  positive Although not statistically significant these correlations warrant further investigation with a larger patient population Despite being in disease remission EGPA patients had decreased quality of life which in turn influenced their perception of their future health outlookEosinophilic granulomatosis with polyangiitis EGPA previously known as Churg–Strauss syndrome is a noninheritable and nontransmissible disease affecting medium and small vessels It is an autoimmune vasculitis leading to tissue necrosis with eosinophilia and eosinophil tissue infiltration 1 EGPA is accompanied by asthma and involves mainly the blood vessels of the lungs gastrointestinal system and peripheral nerves however other organs such as skin kidneys and most notably the heart may also be affected 2 3 Over the years the prognosis for EGPA patients has improved tremendously After the introduction of corticosteroids into therapy 5year mortality rates have decreased to 139  from previously reported 3month rates of approximately 50  4 5 It can be safely said that over the last decade EGPA has been reduced to a chronic relapsing disease usually requiring indefinite medication and periodic followup The question thus arises whether this improvement has had a proportionally positive impact on the quality of life in these patients Additionally the understanding of the term “health” has also changed dramatically during this time and—unsurprisingly—patients’ expectations have evolved correspondingly In fact many of them expect not only to be physically and emotionally healthy but to also enjoy a quality of life similar to that of people unaffected by diseaseQuality of life is defined as an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals expectations standards and concerns 6 Measurement of such a relative parameter is challenging Standardized methods such as the healthrelated quality of life HRQOL Short Form 36 SF36 have become a useful tool in measuring the quality of life of distinct patient populations and comparing it to healthy populations at one moment in time It is also used to monitor the impact of novel treatments methods on the quality of life over a prolonged period of time 7 The additional advantage of using such tools is that they provide a uniform platform which facilitates the comparison of quality of life measurements across similar types of diseases 8Although SF36 has been used in patients with many autoimmune diseases such as granulomatosis with polyangitiis disease GPA Wegener’s granulomatosis 9 systemic lupus erythematosus 10 newly diagnosed antineutrophil cytoplasmic antibody ANCAassociated vasculitis 8 there has been no study using this method that focuses solely on patients with eosinophilic granulomatosis with polyangiitis EGPA patients suffer from a unique set of symptoms that affect their daily lives in ways different from other vasculitic diseases This is partially due to the considerable burden that asthma places on patient’s daily living activities especially before a diagnosis is made 11 Another question that has not been addressed is how patients’ feel about their perceived future health outlook an important yet rarely considered outcome measure 12 and what factors influence this perceptionThese reasons prompted the investigation of whether current quality of life in EGPA patients exerts any influence on their future health outlook Several other significant factors such as gender employment and duration of disease were also screened for correlation with future health outlookMedical records from the Outpatient Allergy and Immunology Clinic of the Jagiellonian University Hospital in Cracow Poland were searched to identify patients with EGPA The diagnosis was verified before enrollment in all patients included in this study As no diagnostic criteria are available for EGPA the American College of Rheumatology ACR classification criteria were used 13 They are the most widely accepted criteria in this condition They distinguish six key features of the disease among them asthma peripheral blood eosinophilia of 10  mono or polyneuropathy paranasal sinus abnormality eosinophilic accumulation in tissues confirmed by a biopsy and migratory infiltrates in lungs At least four of the criteria listed above had to be confirmed in order to validate the diagnosis A custom questionnaire regarding current symptoms current medication regimen and employment history Short Form 36 Health Survey QualityMetrics v 2 as well as future health outlook were included in the survey package The Short Form 36 Health Survey a standardized questionnaire is used to compile two key parameters a mental component score MCS and a physical component score PCS An absolute score 0–100 was obtained for each parameter Using the RAND method a total of eight HRQOL dimensions were measured general health GH physical functioning PF emotional role limitations RE physical role limitations RP social functioning SF mental health MH bodily pain BP and vitality VT A score of 50 was judged to be equivalent to the general population while scores above or below this threshold indicated that a corresponding difference from the normal population was present Using normbased scores we compared the HRQOL of patients with a sample from a general population Patients were also asked to assess how they currently perceive their personal future health outlook as one of three options positive negative or unchanged The available medical documentation and survey data were used to analyze the disease course and evaluate its activity by the Birmingham Vasculitis Activity Score BVAS score BVAS v3 range 0–56 patients available at http//wwwvasculitisorg/diseasehtm 14 Patients with BVAS 2 were assumed to be in disease remission and included to the study The survey packages were mailed to personal home addresses with return postage paid All subjects gave informed consent to participate prior to inclusion in the study Patients answered the survey and mailed it back to the hospital The study protocol complied with the Helsinki Declaration and was approved by the Jagiellonian University Ethics CommitteeStatistical analysis was performed using Statistica Statsoft v100 software Descriptive statistical analyses were performed for all Ninetyfive percent confidence intervals were also calculated on the basis of the Poisson distribution The distributions of the response variables were checked for normality and transformations were performed as appropriate When the pattern of the results observed using the transformed scores was similar to the results obtained from the raw data analysis the raw data analysis is presented if different we report the results obtained using the transformed scores Nonparametric tests were used as appropriate where the normality assumptions could not be met The data were analyzed using Mann–Whitney U tests and Fisher’s test p values less than 005 were considered as statistically significant


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima–media in patients with systemic autoimmune diseases
  2. The virtuoso foot
  3. Responsiveness of the DASH score in surgically treated basal joint arthritis of the thumb: preliminary results
  4. RAPID3 scores and hand outcome measurements in RA patients: a preliminary study
  5. Bone mineral density in children with familial Mediterranean fever
  6. Chorea as a side effect of gabapentin (Neurontin®) in a patient with complex regional pain syndrome Type 1
  7. Risk factors in transient osteoporosis: a retrospective study on 23 cases
  8. Outcome of reactive arthritis after an extensive Finnish waterborne gastroenteritis outbreak: a 1-year prospective follow-up study
  9. Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement
  10. The autonomic nervous system in systemic sclerosis. A review
  11. Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay
  12. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan
  13. Rheumatoid arthritis: should we shift the focus from “Treat to Target” to “Treat to Work?”
  14. Intercellular adhesion molecules in systemic lupus erythematosus patients with lupus nephritis
  15. Severe deficiency of 25-hydroxyvitamin D 3 (25-OH-D 3 ) is associated with high disease activity of rheumatoid arthritis
  16. The expression of death decoy receptor 3 was increased in the patients with primary Sjögren’s syndrome
  17. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)
  18. Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared
  19. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge
  20. Group visits for rheumatoid arthritis patients: a pilot study
  21. Identification of transcription regulatory relationships in rheumatoid arthritis and osteoarthritis
  22. Two cases demonstrating thalidomide’s efficacy in refractory lupus nephritis
  23. Rheumatoid arthritis among Nigerians: the first 200 patients from a rheumatology clinic
  24. The challenge of profound hypoglycorrhachia: two cases of sarcoidosis and review of the literature
  25. Chronic intestinal pseudo-obstruction in patients with systemic lupus erythematosus: report of four cases
  26. Relationship of Q angle and joint hypermobility and Q angle values in different positions
  27. Osteoarthritis of the hip or knee: which coexisting disorders are disabling?
  28. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels
  29. T helper 1 type cytokines polymorphisms: association with susceptibility to Behçet’s disease
  30. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab
  31. Oxidative status in rheumatoid arthritis
  32. Impact and therapy of osteoarthritis: the Arthritis Care OA Nation 2012 survey
  33. Follicular bronchiolitis, an unusual cause of haemoptysis in giant cell arteritis
  34. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature
  35. Vitamin D and systemic lupus erythematosus: state of the art
  36. Challenges and opportunities for diagnosis and treatment of rheumatoid arthritis in Latin America
  37. Clostridium difficile : an under-recognized cause of reactive arthritis?
  38. Prevalence of rheumatic diseases in Raramuri people in Chihuahua, Mexico: a community-based study
  39. Clinical utility of magnetic resonance angiography (MRA) in the diagnosis and treatment of Takayasu’s arteritis
  40. A systematic review of homoeopathy for the treatment of fibromyalgia
  41. Do hip OA patients referred to orthopedic surgeons by general practitioners and rheumatologists differ?
  42. The pathway of estradiol-induced apoptosis in patients with systemic lupus erythematosus
  43. Antistreptococcal Response is Exaggerated in Children with Familial Mediterranean Fever
  44. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register
  45. Beware of the biologicals—hospitals may die: the Rheumatism Foundation Hospital, Heinola, Finland (1951–2010)
  46. Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate
  47. QT dispersion in uncomplicated familial Mediterranean fever
  48. Ultrasonographic evaluation of the muscle architecture in patients with systemic lupus erythematosus
  49. Changes in mononuclear cell function in patients with rheumatoid arthritis following treatment with auranofin
  50. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis
  51. Autonomic dysfunction in psoriatic arthritis
  52. Exercise therapy for patients with diffuse idiopathic skeletal hyperostosis
  53. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients
  54. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis
  55. Increased expression of IL - 28RA mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
  56. Contrast-enhanced power Doppler sonography of knee synovitis in rheumatoid arthritis: assessment of therapeutic response
  57. Long-term follow-up of autologous stem cell transplantation for severe paediatric systemic lupus erythematosus
  58. Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome
  59. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects
  60. Evaluation of a mail-delivered, print-format, self-management program for persons with systemic sclerosis
  61. Serum galectin-3 level in systemic sclerosis
  62. Non-rheumatoid erosive arthritis associated with type I hereditary angioedema
  63. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases
  64. Familial Mediterranean fever responds well to infliximab: single case experience
  65. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases
  66. The role of PET/CT in Cogan’s syndrome
  67. Treatment of osteoporosis in renal insufficiency
  68. STAT4 rs7574865 G/T polymorphism is associated with rheumatoid arthritis and disease activity, but not with anti-CCP antibody levels in a Mexican population

Search Result: